Stimulation of HIV gp120-specific cytolytic T lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector

AIDS Research and Human Retroviruses

Volumn 17, Issue 9, 2001, Pages 819-827

  Carbonetti, N H ^a   Tuskan, R G ^b   Lewis, G K ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BREFELDIN A; CD8 ANTIGEN; DRUG DERIVATIVE; EPITOPE; EPITOPE P18 I10; GENTAMICIN; GLYCOPROTEIN GP 120; HYBRID PROTEIN; HYBRID PROTEIN GP 120 P18 I10; IMMUNOLOGICAL ADJUVANT; KANAMYCIN; LACTACYSTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NALIDIXIC ACID; PERTUSSIS TOXIN; PROTEASOME INHIBITOR; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVITY; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INTRACELLULAR TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL;

ACETYLCYSTEINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIVIRAL AGENTS; BREFELDIN A; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PERTUSSIS TOXIN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRULENCE FACTORS, BORDETELLA;

EID: 0034916501     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750252016     Document Type: Article

References (69)

1. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus
2. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes
3. Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system
4. Induction of protective CTL responses in newborn mice by a murine retrovirus
5. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
6. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
7. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
8. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
9. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
10. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
11. + T cells with a predominant Vβb usage during the primary immune response to HIV
12. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia
13. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in non-infected heterosexual contact of HIV-infected patients
14. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
15. + nef-specific cytotoxic T cells in vaccinated macaques
16. +) T cell depletion in simian immunodeficiency virus-infected macaques
17. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys
18. + lymphocytes
19. Antigen recognition by class I-restricted T lymphocytes
20. Antigen processing and presentation by the class I major histocompatibility complex
21. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules
22. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
23. Subunit structure of the islet-activating protein, pertussis toxin, in conformity with the A-B model
24. The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein
25. Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein)
26. Binding of pertussis toxin to eukaryotic cells and glycoproteins
27. Pertussis toxin has eukaryotic-like carbohydrate recognition domains
28. i-3 in CHO cells is modulated by inhibitors of intracellular trafficking
29. Endocytosis and retrograde transport of pertussis toxin to the Golgi complex as a prerequisite for cellular intoxication
30. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated degradation pathway to enter target cells
31. Mutants of pertussis toxin suitable for vaccine development
32. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
33. Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway
34. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum
35. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules
36. A simple chemically defined medium for the production of phase I Bordetella pertussis
37. Site-directed mutagenesis by overlap extension using the polymerase chain reaction
38. Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen
39. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
40. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
41. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120
42. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes
43. Serum angiotensin-1-converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules
44. Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes
45. Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation
46. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes
47. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
48. Role of A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology
49. Recycling MHC class I molecules and endosomal peptide loading
50. The crystal structure of pertussis toxin
51. Proteolysis and class I major histocompatibility complex antigen presentation
52. The ubiquitin-proteasome proteolytic pathway
53. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo
54. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T lymphocyte responses with non-replicating antigens
55. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo
56. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants
57. Cell-invasive activity of epitope-tagged adenylate cyclase of Bordetella pertussis allows in vitro presentation of a foreign epitope to CD8+ cytotoxic T cells
58. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes
59. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo
60. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein
61. Metabolic, humoral and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G
62. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins
63. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: Adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28
64. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains
65. The B-oligomer of pertussis toxin inhibits human immunodeficiency virus type 1 replication at multiple stages
66. Pertussis toxin inhibits induction of human immunodeficiency virus type 1 in infected monocytes
67. The lymphocytosis-promoting agent pertussis toxin affects virus burden and lymphocyte distribution in the SIV-infected rhesus macaque
68. Anthrax toxin as a molecular tool for CTL vaccination: Disulfide-linked epitopes, multiple injections, and the role of CD4+ cells